Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The scales and tales of myelination: using zebrafish and mouse to study myelinating glia.
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.
The relation between inflammation and neurodegeneration in multiple sclerosis brains.
Inflammatory cortical demyelination in early multiple sclerosis.
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
Astrocyte-derived lactosylceramide implicated in multiple sclerosis.
Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
Gpr126 is essential for peripheral nerve development and myelination in mammals.
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
Chemotherapeutics in the treatment of multiple sclerosis.
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

Pages